Despite the potential benefits, targeting tumor acidity presents several challenges. The heterogeneity of the tumor microenvironment means that pH can vary significantly within different regions of the same tumor. Furthermore, systemic buffering agents can lead to side effects and complications, such as metabolic alkalosis. There is also the risk that altering the pH may inadvertently affect normal tissues and physiological processes.
